#USA #Dallas #thrombectomy #Daniel Davis #Vesalio

Vesalio Appoints Daniel Davis for Strategic Role

In a significant move to enhance its leadership and strategic direction, Vesalio, a leading name in vascular intervention, has officially appointed Daniel Davis to its Board of Directors, simultaneously entrusting him with the role of Advisor to the CEO. This appointment, announced on October 15, 2026, emphasizes Vesalio's commitment to growth and innovation within the rapidly evolving medical device sector.

Daniel Davis brings over 25 years of invaluable experience in the medical device arena, having played pivotal roles in shaping and scaling businesses through strategic leadership. His prior positions at notable companies such as Penumbra and Imperative Care have seen him contribute effectively to product strategy and commercial growth.

A Vision for Growth in Vascular Intervention

In his new position, Davis is expected to provide essential guidance regarding product portfolio priorities and assist in expanding Vesalio's commercial reach. With a focus on the promising data from the NATURE randomized controlled trial (RCT) related to cardiovascular procedures, Davis will spearhead efforts to elevate Vesalio’s presence across coronary, peripheral vascular, and neurovascular markets.

Steve Rybka, Vesalio's CEO, highlighted the significance of Davis's appointment during a period of notable momentum, particularly in light of the positive outcomes from the recent clinical trials. Rybka noted, “Daniel boasts a proven track record of business building from startup stages to public ownership, defining strategies that drive early clinical experiences into market leadership.” This synergy between Rybka and Davis aims to refine the company's focus on high-impact opportunities that promise to accelerate execution and organizational scaling.

Building on a Foundation of Success

Davis's extensive career showcases a history of leadership roles that reflect his capability to navigate the intricate landscape of medical devices. His tenure at Imperative Care was marked by transformative growth, where he fulfilled leadership positions including that of President and COO. This was coupled with a successful journey at Penumbra, where he was instrumental in steering the company from its nascent stages through to a successful IPO.

Davis emphasized Vesalio's mission, stating, “The challenges presented in coronary, neurovascular, and peripheral thrombectomy represent critical unmet clinical needs. The successful outcomes published from the NATURE RCT herald a pivotal moment for us and a catalyst for upcoming growth phases.” This assertion underscores his commitment to leveraging his expertise for advancements in patient care.

Looking Ahead: Commitment to Innovation

At the heart of Vesalio's approach is a focus on innovation and responsiveness to the needs of healthcare providers. Davis plans to collaborate closely with physicians to enhance Vesalio's thrombectomy solutions, refining procedural workflows that address significant clot burdens in patients. This proactive strategy aims to optimize patient outcomes and establish Vesalio as a vanguard in the vascular intervention landscape.

About Vesalio

Vesalio is dedicated to pioneering advances in the treatment of thromboembolic vascular diseases. The company is recognized for its proprietary technologies that empower physicians to remove all types of clots, crucially restoring blood flow to ischemic areas, including the heart, brain, and peripheral circulation. With a strong presence in over 60 countries and more than 20,000 patients treated, Vesalio stands poised for substantial growth as it transitions into this new phase under Davis's strategic advisory.

For further information on Vesalio’s endeavors and its commitment to transforming vascular care, visit www.vesalio.com.